Alzheimer’s Research Program Transforming Care Award
ID: 358721Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358721
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Care Award to support innovative clinical research aimed at improving care for individuals with Alzheimer's disease and related dementias (AD/ADRD). This funding opportunity encourages community collaboration and requires projects to focus on interventions that enhance the quality of life for both patients and their caregivers. Approximately $5.2 million is available to fund around three awards, with pre-applications due by June 12, 2025, and full applications due by August 29, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY25.pdf
    The Fiscal Year 2025 Department of Defense Alzheimer’s Research Program (AZRP) outlines various award mechanisms aimed at advancing research on Alzheimer's disease and related dementias (AD/ADRD) and traumatic brain injury (TBI). Three primary awards are detailed: the Transforming Diagnosis Award, the Transforming Research Award, and the Transforming Care Award. Each award supports innovative studies that require community collaboration and prohibits clinical trials while allowing the use of existing data. The Transforming Diagnosis Award, with a maximum funding limit of $1.5M for the base option and $1.7M for career initiation or transition (CIT), focuses on enhancing diagnostic methods for AD/ADRD. The Transforming Research Award, limited to $1.0M, aims to mitigate risks and improve patient care through transformative research. The Transforming Care Award emphasizes person-centered research, allowing clinical trials, with funding up to $1.6M and $1.8M for CIT. All three awards require preliminary data submission, a pre-proposal for invited applications, and adherence to community collaboration. Submission deadlines for pre-proposals and applications fall on June 12, 2025, and August 29, 2025, respectively. This initiative underscores the federal commitment to improving outcomes for military personnel affected by AD/ADRD and TBI through strategic research support.
    HT942525AZRPTrCA.pdf
    The Department of Defense’s FY25 Alzheimer’s Research Program is announcing the availability of funding for the Transforming Care Award, aimed at supporting innovative research focused on improving care for individuals with Alzheimer’s disease and related dementias. The program encourages applications from a diverse range of eligible organizations, including for-profit and non-profit entities, with a special emphasis on community collaboration. Approximately $5.2 million is allocated to fund around three awards, with specific cost caps depending on the type of application (single PI or partnership). Pre-applications are due by June 12, 2025, followed by a full application deadline of August 29, 2025. Successful projects should demonstrate innovative approaches to address caregiver burden, improve quality of life, and incorporate community perspectives. The awards can last up to four years and will finalize funding decisions by September 2026. A two-step application process requires initial pre-proposals, which must include a narrative outlining the research's significance and impact, followed by a comprehensive full application for those invited. Review criteria will assess the project’s impact, feasibility, strategy, and integration of community collaboration, ensuring that research meets the needs of those affected by Alzheimer's and related conditions. This initiative reflects a commitment to advance care and support for a vulnerable population while fostering cross-disciplinary cooperation.
    Similar Opportunities
    Alzheimer’s Research Program Transforming Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Research Award to support innovative research aimed at reducing the risk of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages diverse applicants, including for-profit, non-profit, and academic institutions, and emphasizes the necessity of community collaboration, particularly for clinical research projects. With an estimated total program funding of $4 million, the program anticipates awarding approximately four grants, each providing up to $1 million over a maximum of three years. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025. For further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer’s Research Program Transforming Diagnosis Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Diagnosis Award to support innovative research aimed at enhancing the diagnosis and prognosis of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages community collaboration and requires the submission of preliminary data, with a focus on addressing barriers to effective dementia diagnosis. With an estimated total program funding of $3.2 million, the program anticipates awarding two grants, with funding caps set at $1.5 million for single Principal Investigator (PI) proposals and $1.7 million for those utilizing the Career Initiation or Transition Partnership Option. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Development Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) to support innovative research aimed at developing therapies for Amyotrophic Lateral Sclerosis (ALS). This grant program seeks applications that demonstrate proof-of-concept efficacy in preclinical models of ALS, with a focus on empirical therapeutic studies and the development of mechanism-specific biomarkers to enhance trial design and patient selection. With an estimated total funding of approximately $9.8 million, the program anticipates awarding about four grants, each capped at $1.5 million for a maximum duration of three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Pilot Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award to support clinical trials aimed at improving the treatment and management of Amyotrophic Lateral Sclerosis (ALS). Applicants are required to focus on either biomarker-driven interventions or enhancements in clinical care, with an emphasis on incorporating community collaboration to optimize research impact. This funding opportunity allocates approximately $6.6 million to support around two pilot clinical trial applications, with a direct cost cap of $2 million for each project. Interested parties must submit a pre-application by June 6, 2025, followed by a full application due on August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This grant aims to support the development and validation of clinical outcomes and biomarkers specifically for enhancing clinical trials in Amyotrophic Lateral Sclerosis (ALS), focusing on targeted therapies or genetic mutations rather than broad applicability to all patients. With an estimated total program funding of $6.2 million, the program anticipates awarding approximately five grants, each with a maximum budget of $750,000 for a duration of up to three years. Interested applicants must submit a pre-application by June 6, 2025, followed by a full application due by August 27, 2025. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Peer Reviewed Medical Research Program, Clinical Trial Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity under the Peer Reviewed Medical Research Program (PRMRP) for the fiscal year 2025, specifically for the Clinical Trial Award (CTA). This program aims to support the rapid implementation of clinical trials that can significantly impact the treatment or management of diseases relevant to military health, with a focus on areas such as autoimmune disorders, cardiovascular health, infectious diseases, and neuroscience. Approximately $32 million is available for this initiative, with an expected four awards, each capped at $8 million, and applications are due by July 21, 2025. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Duchenne Muscular Dystrophy, Clinical/Translational Research Award
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a grant opportunity for the Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award (CTRA) for fiscal year 2025. This funding initiative aims to support advanced translational research that accelerates promising ideas in Duchenne muscular dystrophy (DMD) into clinical applications, particularly focusing on therapies effective across all age groups, including infants and nonambulatory individuals. With an estimated total program funding of approximately $8.56 million, the program anticipates awarding around five grants, encouraging collaborations with early-career investigators and requiring applications to include preliminary data relevant to DMD. Interested applicants should note that a pre-application is due by July 25, 2025, with full applications due by August 8, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.